Solvay Expects Advisory Cmte. Review For Irritable Bowel Agent Cilansetron
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs and Drug Safety & Risk Management Advisory Committees are expected to discuss cilansetron at a March 9 joint meeting. The agency extends the Jan. 1 user fee deadline for the NDA by 90 days to April 1.
You may also be interested in...
Solvay Preparing Announcement On Cilansetron NDA
Solvay receives a response letter from FDA one week ahead of the user fee deadline for the irritable bowel syndrome product. Solvay is currently assessing the letter's contents, the company says.
Solvay Preparing Announcement On Cilansetron NDA
Solvay receives a response letter from FDA one week ahead of the user fee deadline for the irritable bowel syndrome product. Solvay is currently assessing the letter's contents, the company says.
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Fournier's co-marketing agreement with Abbott for the lipid-lowering product will remain unchanged following Solvay's €1.3 bil. acquisition of the French company. Solvay will build a new cardio-metabolic division from Fournier, to be headquartered in Paris.